Introduction Approximately $60 billion in US Humira sales will remain uncontested over the next four years...
Introduction With over a decade of real world biosimilar experience in Europe and now more than...
Introduction With the recent announcement that NeuClone is developing a biosimilar candidate of Perjeta (pertuzumab), this...
Introduction Five biosimilar copies of the world’s highest selling drug, Humira (adalimumab), are about to launch...
Introduction With 27 speakers and 78 follow-up electronic submissions, the Food and Drug Administration’s (FDA) recent...
In recent years biosimilar regulatory requirements across the world have converged and a broadly accepted...
The NeuClone Biosimilar Brief is a biosimilar industry publication written by NeuClone exploring biosimilar related...